TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00598650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
Study: NCT04754763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentin-Bonding Agents
Description: 3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
Study: NCT01628913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 400 mg bid p.o. (by mouth, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg qd p.o. (by mouth, daily)
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study: NCT00011986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02015247

Intervention type: PROCEDURE
Group type: OTHER
Intervention: computer-assisted surgery
Description: use of computer-assisted navigation during periacetabular osteotomy
Study: NCT00905229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonadione
Description: 2.5 mg po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonadione
Description: 0.5 mg IV
Study: NCT04391712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS Laser
Description: Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study: NCT00595413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Study: NCT04391712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Inpatient Medical Care
Description: Regular inpatient medical care
Study: NCT01426061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology plus conventional treatment
Description: Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy plus conventional treatment
Description: Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Conventional treatment
Description: Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
Study: NCT03502564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for ED
Description: Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent CBT for ED and PTSD
Description: The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
Study: NCT01606579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724
Study: NCT01061736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: According to local standard
Study: NCT01606579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724 in combination with dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724 in combination with dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724 in combination with low dose ara-C therapy
Study: NCT02441842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Description: administered 60 minutes pre procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: administered 60 minutes pre procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: administered 60 minutes pre procedure
Study: NCT03730584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
Study: NCT00372957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 15mg
Description: White opaque capsule containing 15mg of GW823093 as free base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 placebo capsule
Description: Matching placebo of GW823093 capsule or 15mg capsule
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard
Study: NCT00372957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093 placebo capsule
Description: Matching placebo of GW823093 capsule or 15mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 30mg
Description: White opaque capsule containing 15mg of GW823093 as free base
Study: NCT02701764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard
Study: NCT02701764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00781547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human growth hormone
Description: The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
Study: NCT03246087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture
Description: acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupunture
Description: acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care home exercise program
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard
Study: NCT04160104

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.

Intervention type: OTHER
Intervention: Questionnair
Description: Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
Study: NCT00352300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given IV
Study: NCT03816189

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsies
Description: In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsies
Description: In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
Study: NCT01047189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate 1.2% and tretinoin 0.025%
Description: applied once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin 1% gel
Description: Topical clindamycin applied each morning for 12 weeks
Study: NCT01047189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin 0.025% cream
Description: Tretinoin 0.025% cream each evening for 12 weeks
Study: NCT02332187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active electrical stimulation using an All Stim stimulator
Description: This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
Study: NCT02570529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albis®
Description: The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Study: NCT02189590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q
Description: Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
Study: NCT03782636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile diluent used for the aldesleukin preparation and 5% glucose
Study: NCT02871401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Study: NCT02332187

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation using an All Stim stimulator
Description: With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
Study: NCT01370187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 4mg daily for 2 months
Study: NCT00595413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept: with loading dose
Description: Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
Study: NCT03407092

Intervention type: OTHER
Intervention: ADAPT cohort
Description: Thrombectomy with distal aspiration technique

Intervention type: OTHER
Intervention: Stentriever Cohort
Description: Thrombectomy with stent retriever
Study: NCT04515888

Intervention type: OTHER
Intervention: PFDI-20 / PFIQ-7 questionnaires
Description: PFDI-20 / PFIQ-7 questionnaires (one shot)

Intervention type: OTHER
Intervention: PFDI-20 / PFIQ-7 questionnaires
Description: PFDI-20 / PFIQ-7 questionnaires (one shot)
Study: NCT02871401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Study: NCT01049373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDC
Description: (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 10 drops, t.i.d, 15 weeks
Study: NCT03030456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Plate®
Description: Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
Study: NCT01805284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
Study: NCT03663855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin
Description: Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
Study: NCT04343092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Description: Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
Study: NCT01148667

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein hydrolysate added with LGG
Description: Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
Study: NCT03522883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise
Study: NCT01148667

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infants drink casein hydrolysate without LGG
Description: Infants drink extensively hydrolysed casein formula without added LGG
Study: NCT03522883

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise
Study: NCT03712800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmical massage
Description: Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
Study: NCT00595413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
Study: NCT00200200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab HAI plus systemic chemotherapy
Description: Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
Study: NCT02860442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone brief intervention (SP-BI)
Description: Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan.
Study: NCT03712800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
Study: NCT04899960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention
Description: Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
Study: NCT01766479

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT colonography
Study: NCT00214968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: maximum dosage 400 mg/day (4 tablets)
Study: NCT02477293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyeonggaeyeongyo-tang
Study: NCT02860442

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
Study: NCT01833533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ribavirin
Description: Capsule
Study: NCT01170910

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Static incubation
Description: Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Description: Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted